Immunotherapy for Renal Cell Carcinoma
Open Access
- 3 January 2010
- journal article
- review article
- Published by Wiley in Journal of Immunology Research
- Vol. 2010 (1) , 284581
Abstract
Immunotherapy plays a significant role in the management of renal cell carcinoma (RCC) patients with metastatic disease because RCC is highly resistant to both chemotherapy and radiation therapy. Many reports illustrate various approaches to the treatment of RCC, such as cytokine‐, antigen‐ or dendritic cell‐ (DC‐) based immunotherapy, and the safety and effectiveness of immunotherapy have been highlighted by multiple clinical trials. Although antitumor immune responses and clinically significant outcomes have been achieved in these trials, the response rate is still low, and very few patients show long‐term clinical improvement. Recently, the importance of immune regulation by antigen‐presenting cells (APC) and regulatory T cells (Treg cells) has also been discussed. The authors outline the principles of cell‐mediated tumor immunotherapy and discuss clinical trials of immunotherapy for RCC.Keywords
This publication has 77 references indexed in Scilit:
- Phase 1 Trial of Allogeneic Gene-Modified Tumor Cell Vaccine RCC-26/CD80/IL-2 in Patients with Metastatic Renal Cell CarcinomaHuman Gene Therapy, 2010
- Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell CarcinomaJournal of Immunotherapy, 2008
- Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findingsBritish Journal of Cancer, 2008
- Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinomaClinical Immunology, 2007
- Immunotherapy against metastatic renal cell carcinoma with mature dendritic cellsInternational Journal of Urology, 2007
- Preliminary Analysis of Patients With Progressive Renal Cell Carcinoma Vaccinated With CA9-peptide–Pulsed Mature Dendritic CellsJournal of Immunotherapy, 2007
- Renal Cancer Treatment with Low Levels of Mixed Chimerism Induced by Nonmyeloablative Regimen Using Cyclophosphamide in MiceCancer Research, 2005
- Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinomaCancer, 2003
- Therapeutic Vaccination against Metastatic Carcinoma by Expression-Modulated and Immunomodified Autologous Tumor Cells: A First Clinical Phase I/II TrialHuman Gene Therapy, 2001
- Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guèrin: Five-year results of a prospective randomized studyCancer, 1996